UBX0101

DRUG3 trials

Sponsors

Unity Biotechnology, Inc.

Conditions

Knee OsteoarthritisOsteoarthritis, Knee

Phase 1

A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee

CompletedNCT03513016

Unity Biotechnology, Inc.Osteoarthritis, Knee

Start: 2018-05-16End: 2019-04-12Updated: 2020-04-20

A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee

CompletedNCT04229225

Unity Biotechnology, Inc.Knee Osteoarthritis

Start: 2020-01-23End: 2020-09-18Updated: 2020-10-19

Phase 2

A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee

CompletedNCT04129944

Unity Biotechnology, Inc.Osteoarthritis, Knee

Start: 2019-10-30End: 2020-08-07Updated: 2021-12-29

Related Papers

Therapeutic subtypes of knee osteoarthritis: differential treatment effects among predicted endotypes in past clinical trials

Arthritis Research & Therapy2026-05-07

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.

2019-09-18951 citations